Showing results (41-50 of 113) with videos related to
Sort By:
Pageof 12
The Lancet. Haematology|October 22, 2020
Consensus treatment recommendations from the tenth International Workshop for Waldenström MacroglobulinaemiaJorge J Castillo, Ranjana H Advani, Andrew R Branagan, et al.Nature Medicine|July 3, 2023
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim resultsJae H Park, Karthik Nath, Sean M Devlin, et al.Blood Advances|September 16, 2021
Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?Brandon S Imber, Karen W Chau, Jasme Lee, et al.Blood Advances|October 29, 2024
Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomesYannis K Valtis, Sean Devlin, Roni Shouval, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.Haematologica|August 30, 2023
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomesPaola Ghione, Salma Ahsanuddin, Efrat Luttwak, et al.Future Oncology (London, England)|February 23, 2023
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemiaChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.Blood|June 4, 2026
Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCLJeremy S Abramson, Tanya Siddiqi, Leo I Gordon, et al.Blood Cancer Journal|August 8, 2020
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphomaKitsada Wudhikarn, M Lia Palomba, Martina Pennisi, et al.Lancet (London, England)|September 5, 2020
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyJeremy S Abramson, M Lia Palomba, Leo I Gordon, et al.Pageof 12